➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Baxter
Colorcon
AstraZeneca
Mallinckrodt
Harvard Business School

Last Updated: October 23, 2021

DrugPatentWatch Database Preview

Claims for Patent: 9,770,416


Email this page to a colleague

« Back to Dashboard

Summary for Patent: 9,770,416
Title:Tamper resistant dosage forms
Abstract: The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.
Inventor(s): McKenna; William H. (Yonkers, NY), Mannion; Richard O. (Furlong, PA), O'Donnell; Edward P. (Basking Ridge, NJ), Huang; Haiyong H. (Princeton, NJ)
Assignee: PURDUE PHARMA L.P. (Stamford, CT) PURDUE PHARMACEUTICALS L.P. (Wilson, NC)
Application Number:15/413,678
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,770,416
Patent Claims: 1. A pharmaceutical composition comprising: at least one active agent comprising an opioid or a pharmaceutically acceptable salt thereof; at least one high molecular weight polyethylene oxide (PEO), having an approximate molecular weight of from 1 million to 8 million; optionally at least one low molecular weight PEO having an approximate molecular weight of less than 1,000,000; wherein (a) the active agent and high molecular weight PEO are combined in a solid oral extended release dosage form that is (i) compression shaped, (ii) air cured by heated air, without compression, for a curing time of about 15 minutes to about 8 hours at a curing temperature of about 60.degree. C. to about 90.degree. C., (iii) cooled, and (iv) hardened; (b) the high molecular weight PEO is at least partially melted upon curing and comprises at least about 50% (by weight) of the dosage form; (c) the active agent comprises at least about 1.3% (by weight) of the dosage form; (d) the molecular weight of each PEO is based on rheological measurements; (e) the total weight of the dosage form is calculated by excluding the combined weight of said film coatings; and (f) the dosage form is expanded upon curing, as measured by a decrease in density of at least about 1.5%, and the dosage form provides a hardness of at least about 439 N.

2. A pharmaceutical composition according to claim 1, wherein the high molecular weight PEO is selected from at least one PEO having an approximate molecular weight of 1 million, 2 million, 4 million, 5 million, 7 million, and 8 million.

3. A pharmaceutical composition according to claim 2, wherein the active agent (i) is selected from the group consisting of buprenorphine, oxycodone, oxymorphone, hydrocodone, hydromorphone, morphine, and pharmaceutically acceptable salts thereof.

4. A pharmaceutical composition according to claim 3, wherein the active agent comprises at least about 2.4% (by weight) of the dosage form.

5. A pharmaceutical composition according to claim 4, wherein the curing temperature is from about 70.degree. C. to about 85.degree. C. and the curing time is from about 15 minutes to about 5 hours.

6. A pharmaceutical composition according to claim 5, wherein the low molecular weight PEO is present, has an approximate molecular weight of from 100,000 to 900,000, and comprises at least about 10% (by weight) of the dosage form.

7. A pharmaceutical composition according to claim 5, wherein the low molecular weight PEO is present, has an approximate molecular weight of from 100,000 to 900,000, and comprises at least about 20% (by weight) of the dosage form.

8. A pharmaceutical composition according to claim 7, wherein the active agent is a tartrate salt of hydrocodone, the high molecular weight PEO is selected from 4 million and 7 million, and the high and low molecular weight PEO together comprise at least about 80% (by weight) of the dosage form.

9. A pharmaceutical composition according to claim 3, wherein the active agent comprises at least about 5% (by weight) of the dosage form.

10. A pharmaceutical composition according to claim 9, wherein the curing temperature is from about 70.degree. C. to about 85.degree. C. and the curing time is from about 15 minutes to about 5 hours.

11. A pharmaceutical composition according to claim 10, wherein the active agent is oxycodone hydrochloride, and the high molecular weight PEO is selected from 4 million and 7 million, and comprises at least about 65% (by weight) of the dosage form.

12. A pharmaceutical tablet comprising: a dosage amount of least one active agent comprising an opioid or a pharmaceutically acceptable salt thereof; at least one high molecular weight polyethylene oxide (PEO) having an approximate molecular weight of from 1 million to 8 million; at least one additive comprising an anti-tacking agent, an antioxidant, an immediate release component, or a retardant; at least one film coating; and optionally at least one low molecular weight PEO having an approximate molecular weight of less than 1,000,000; wherein (a) the active agent and high molecular weight PEO are combined in a solid oral extended release tablet that is (i) shaped by direct compression, (ii) air cured by heated air, without compression, for a curing time of at least 15 minutes at a curing temperature of at least about 65.degree. C., (iii) cooled at a cooling temperature below about 50.degree. C., and (iv) hardened; (b) the high molecular weight PEO comprises at least about 50% (by weight) of the dosage form; (c) the active agent comprises at least about 2.4% (by weight) of the dosage form; (d) the molecular weight of each PEO is based on rheological measurements; and (e) the total weight of the dosage form is calculated by excluding the combined weight of said film coatings; and (f) the dosage form is expanded upon curing, as measured by a decrease in density of at least about 1.5%, and the dosage form provides a hardness of at least about 439 N.

13. A pharmaceutical composition according to claim 12, wherein at least one additive comprises an anti-tacking agent; the compression shaped tablet is cured and cooled in a convection curing device provided with inlet air, exhaust air, and a bed of free flowing tablets; and each of the curing temperature and the cooling temperature is one of (a) the temperature of the inlet air, or (b) the temperature of the exhaust air.

14. A pharmaceutical composition according to claim 13, wherein the convection curing device is a coating pan.

15. A pharmaceutical composition according to claim 14, wherein the curing temperature has a plateau-like profile.

16. A pharmaceutical composition according to claim 15, wherein each of the curing temperature and cooling temperature is the temperature of the exhaust air.

17. A pharmaceutical composition according to claim 16, wherein the cooling temperature is from about 30.degree. C. to about 34.degree. C.

18. A pharmaceutical composition according to claim 16, wherein the low molecular weight PEO is present, has an approximate molecular weight of from 100,000 to 900,000, and comprises at least about 20% (by weight) of the dosage form.

19. A pharmaceutical composition according to claim 16, wherein at least one of the additive and the film coating comprises at least one of butylated hydroxytoluene (BHT), magnesium stearate, talc, silica, fumed silica, colloidal silica dioxide, calcium stearate, carnauba wax, stearic acid, stearyl alcohol, mineral oil, paraffin, micro crystalline cellulose, glycerin, propylene glycol, polyethylene glycol, lactose, povidone, triacetin, and hydroxypropyl cellulose.

20. A pharmaceutical composition according to claim 16, wherein at least one additive is magnesium stearate.

21. A pharmaceutical composition according to claim 16, wherein the tablet, when subjected to about 15,000 pounds of applied pressure from a hydraulic press, provides a flattened tablet that is flattened without breaking apart; has a thickness that is no more than about 50% of the thickness of the non-flattened tablet; and provides a dissolution of active agent, with ethanol, that deviates no more than about 15% points from the dissolution of a non-flattened reference tablet, without ethanol; wherein dissolution is measured (i) as a percent amount of active agent released at selected time points up to and including at least a 2 hour period; (ii) using a USP Apparatus 1 (basket) at 37.degree. C. and 100 rpm, in 900 ml simulated gastric fluid without enzymes (SGF) for the non-flattened tablet, and further comprising 40% ethanol for the flattened tablet.

22. A pharmaceutical composition according to claim 21, wherein the tablet, when measured (a) without an antioxidant additive and (b) as the average of at least 10 of 100 tablet samples stored at 40.degree. C. and 75% relative humidity for at least 3 months; provides a dissolution of the active agent that deviates no more than about 10% points from the dissolution of a reference tablet before storage; wherein dissolution is measured (i) as a percent amount of active agent released at selected time points up to and including at least a 12 hour period; (ii) using a USP Apparatus 1 (basket) at 37.degree. C. and 100 rpm, in 900 ml simulated gastric fluid without enzymes (SGF).

23. A pharmaceutical composition according to claim 22, wherein the deviation in dissolution upon flattening is no more than about 15% points and the deviation in dissolution upon storage is no more than about 5% points.

24. A pharmaceutical composition according to claim 23, wherein the deviation in dissolution upon storage is no more than about 3% points.

25. A pharmaceutical composition according to claim 23, wherein the stored dosage form comprises degradation products of the active agent in a total amount that is no greater than about 0.1% (by weight) of the dosage amount.

26. A pharmaceutical composition according to claim 23, wherein the high molecular weight PEO has an approximate molecular weight selected from 4 million and 7 million.

27. A pharmaceutical composition according to claim 23, wherein the tablets are stored for at least 6 months.

28. A pharmaceutical composition according to claim 27, wherein the stored dosage form comprises degradation products of the active agent in a total amount that is no greater than about 0.1% (by weight) of the dosage amount.

29. A pharmaceutical composition according to claim 28, wherein the active agent is a pharmaceutically acceptable salt of oxycodone and the tablet is suitable for twice-daily administration.

30. A pharmaceutical composition according to claim 28, wherein the active agent is a pharmaceutically acceptable salt of hydrocodone and the tablet is suitable for once-daily administration.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Moodys
AstraZeneca
Boehringer Ingelheim
Harvard Business School
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.